Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | CAR.k.28 cells |
Synonyms | |
Therapy Description |
CAR.k.28 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the kappa-light chain antibody linked to CD28 endodomain, which potentially induce cytotoxicity against Kappa-positive tumor cells (PMID: 16926291, NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CAR.k.28 cells | ATLCAR.k.28|ATLCAR.kappa.28 | CAR.k.28 cells are autologous T-lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting the kappa-light chain antibody linked to CD28 endodomain, which potentially induce cytotoxicity against Kappa-positive tumor cells (PMID: 16926291, NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00881920 | Phase I | CAR.k.28 cells Cyclophosphamide + Fludarabine | Kappa-CD28 T Lymphocytes, Chronic Lymphocytic Leukemia, B-cell Lymphoma or Multiple Myeloma, CHARKALL (CHARKALL) | Recruiting | USA | 0 |